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Abstract: Nitric oxide (NO)-mediated vasodilation plays a key role in gastric mucosal 
defense, and NO-donor drugs may protect against diseases associated with gastric mucosal 
blood flow (GMBF) deficiencies. In this study, we used the ex vivo gastric chamber method 
and Laser Doppler Flowmetry to characterize the effects of luminal aqueous NO-donor 
drug S-nitroso-N-acetylcysteine (SNAC) solution administration compared to aqueous NaNO2 
and NaNO3 solutions (pH 7.4) on GMBF in Sprague-Dawley rats. SNAC solutions (600 μM 
and 12 mM) led to a rapid threefold increase in GMBF, which was maintained during the 
incubation of the solutions with the gastric mucosa, while NaNO2 or NaNO3 solutions  
(12 mM) did not affect GMBF. SNAC solutions (600 μM and 12 mM) spontaneously released 
NO at 37 °C at a constant rate of 0.3 or 14 nmol·mL−1·min−1, respectively, while NaNO2 
(12 mM) released NO at a rate of 0.06 nmol·mL−1·min−1 and NaNO3 (12 mM) did not 
release NO. These results suggest that the SNAC-induced GMBF increase is due to their 
higher rates of spontaneous NO release compared to equimolar NaNO2 solutions. Taken 
together, our data indicate that oral SNAC administration is a potential approach for gastric 
acid-peptic disorder prevention and treatment. 
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1. Introduction 
In mammalian cells nitric oxide (NO) is synthesized by NO synthases (NOS) from L-arginine, and 
it mediates several biological processes, including neurotransmission, vasodilation, host defense and 
immunity [1]. NO-mediated vasodilation is a fundamental gastric mucosa defense mechanism, as impaired 
blood supply to the stomach renders the mucosa more susceptible to acid and pepsin-induced injuries [2]. 
In addition, the NO actions on gastric physiology include the modulation of gastric mucous formation [3] 
and antimicrobial activity [4], the reduction of mast cell degranulation and release, neutrophil adherence 
and secretion, macrophage cytokine release and epithelial barrier function regulation [5–7] and its possible 
involvement in the protective effects of angiotensin (1–7) on gastroesophageal reflux [8]. 
Cyclooxygenase inhibition in the gastrointestinal mucosa by nonsteroidal anti-inflammatory drugs 
(NSAIDs) is associated with GMBF alterations, which leads to gastrointestinal injury as a common 
NSAID side effect [9]. Widespread and intense NSAID use has generated an important demand for 
gastrointestinal injury prevention, which has led to modified NSAID design and development in which 
NO donor moieties are chemically attached to allow for local NO release in the stomach. This gastric 
mucosal blood flow regulation by combining NSAIDs with local NO release proved to be a valid and 
efficacious approach to prevent NSAID-induced gastric lesions [10]. As new modified NSAID 
development requires novel synthetic routes and clinical trials, an alternative approach is the development 
of formulations, which combine standard oral NSAIDs with an NO donor drug in a physical mixture. 
The efficacy of this combination was recently reported by Tam et al. [11], who showed that 
co-administration of the well-known NO donor S-nitrosoglutathione (GSNO) with piroxicam inhibited 
NSAID-associated gastric lesions. 
Like GSNO, S-nitroso-N-acetylcysteine (SNAC) (Figure 1) is a primary S-nitrosothiol (RSNO) 
derived from N-acetylcysteine (NAC) S-nitrosation. Both GSNO and SNAC have been shown to be 
potent vasodilators in vivo [12,13], and oral aqueous SNAC administration in animals with impaired 
NO production have therapeutic effects [14–16]. However, SNAC’s vasodilator effect on GMBF and 
its potential for protecting the gastric mucosa against acids or pepsin injuries has not been investigated.  
In this study, we evaluated the effect of luminal SNAC solution administration on Sprague Dawley 
rat GMBF compared to the effects of sodium nitrite (NaNO2) and sodium nitrate (NaNO3) solutions at 
pH 7.4 using Laser Doppler Flowmetry. We observed a significant increase in GMBF upon SNAC 
solution treatment, but NaNO2 and NaNO3 solutions had no effect. The GMBF increase correlated with 
the spontaneous NO release from SNAC, as measured by chemiluminescence. 
 
Figure 1. Structure of S-nitroso-N-acetylcysteine (SNAC).  
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2. Results and Discussion 
2.1. NO Release Profiles 
Figure 2 shows the chemiluminescence profiles of spontaneous NO released from 600 μM and  
12 mM SNAC (A, B) and from 12 mM NaNO2 and NaNO3 solutions (C, D) over 10 min at 37 °C and 
pH 7.4, along with the corresponding total released NO, which was calculated from these curves (E). 
We observed a narrow chemiluminescence peak in each curve immediately after solution injection. 
After these initial peaks, NO release rates for the 600 µM SNAC, 12 mM SNAC and 12 mM NaNO2 
plateaued above the initial baseline, and maintained their level over the remaining measurement times. 
The shift of these plateaus from the baseline can be seen more clearly in the insets of Figure 2A,B. 
After NaNO3 injection, the chemiluminescence signal did not shift from the baseline, and the 
extremely narrow initial peak was too low to quantify. We obtained total released NO values after 
SNAC and NaNO2 injection (expressed per mL per min) from the integrations of total area under the 
curves (over 600 s) (Figure 2E). The NO release rates from 600 μM and 12 mM SNAC were  
0.3 nmol·mL−1·min−1 and 14 nmol·mL−1·min−1, respectively, compared to 0.06 nmol·mL−1·min−1 for 
the NaNO2 solution. Therefore, 12 mM SNAC releases NO at a rate 46 times higher than 600 μM 
SNAC, and 600 μM SNAC and 12 mM SNAC release NO at rates 5 and 233 times higher than 12 mM 
NaNO2 solution, respectively. 
 
Figure 2. Chemiluminescence detection of NO release from 12 mM SNAC (A) and 600 μM 
SNAC (B) and 12 mM NaNO2 and NaNO3 solutions (C and D, respectively) over 10 min 
at 37 °C, and the total NO release (E) extracted from these curves. The baseline trace was 
recorded for PBS, pH 7.4. Error bars are the SEM of triplicates. a.u., arbitrary units.  
2.2. Gastric Blood Flow Measurements by Laser Doppler Flowmetry 
Figure 3 shows the GMBF profiles for control and SNAC-treated animals. Importantly, control 
animals were exposed only to PBS solution for the full 20 min (basal readings plus test reading), while 
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the gastric mucosas of the treated animals were incubated in PBS during the first 3 min to record their 
basal GMBF, then the PBS was replaced by SNAC, NaNO2 or NaNO3. The GMBF of the control 
group remained stable throughout the 20-min period at a value of approximately 1.0 tissue perfusion 
units (T.P.U). The treated groups had similar stable baseline GMBF values in PBS during the first  
3 min. However, when the PBS was replaced by SNAC, the GMBF rapidly increased with onsets  
at 3 and 5 min after 12 mM and 600 μM SNAC application, respectively. Both SNAC treatment 
groups reached similar GMBF peaks (2.5–3 T.P.U) after 4 to 5 min. In addition, increased GMBF 
values remained close to the peak values during SNAC incubation periods (from 3 to 13 min), but they 
slowly decreased after SNAC was replaced with PBS over the next 7 min until reaching the basal level 
after approximately 4 min. Notably, the 12 mM SNAC solution, which has a concentration 20 times 
higher than the 600 μM solution, led only to a slightly earlier increase in GMBF onset but not to a 
higher peak or a slower return to the baseline. In contrast to the GMBF profiles after SNAC 
application, luminal application of 12 mM NaNO2 or NaNO3 did not significantly change the basal 
GMBF over the same time periods (Figure 4). 
 
Figure 3. Ex vivo Laser Doppler measurements of rat gastric mucosal blood flow in a 
gastric chamber after incubation with PBS only over 20 min (control) or PBS for 3 min, 
followed by 600 μM or 12 mM SNAC for the next 10 min, which were replaced by PBS 
during the last 7 min, as indicated by the horizontal bars. The results are expressed as the 
mean ± S.E.M. of triplicates. 
2.3. Quantification of Plasma NOx Levels 
Figure 5 shows the time-course of the plasma NOx concentrations 30, 60, 120 and 180 min after 
oral 12 mM SNAC administration to Swiss mice. We observed a significant increase in absolute 
plasma NOx levels at all time points, and the maximum increase (relative to the basal level) occurred 
after 60 min. After this time, plasma NOx levels began to decrease, although the levels were still 
significantly higher than basal levels 2 h after gavage. Figure 6 shows the dose-response of plasma 
NOx concentration 1 h after 1.2, 12 and 60 mM (corresponding to 7.0 μmol/kg, 70 μmol/kg and  
350 μmol/kg, respectively) oral SNAC administration to Swiss mice compared to control naive 
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animals and to animals that received only distilled water. While the plasma NOx concentration of the 
animals that received 1.2 mM SNAC did not significantly change compared to control animals 
(approximately 20 μM), 12 and 60 mM SNAC administration led to a significant dose-response 
increase in plasma NOx concentrations, which reached 45 ± 12 µM and 103 ± 15 µM, respectively. 
For this reason, we chose 12 mM SNAC and equimolar NaNO2 and NaNO3 solutions as the highest 
concentrations for evaluating their effects on the GMBF increase and time course of plasma NOx 
levels after oral SNAC administration, as described above. 
 
Figure 4. Ex vivo Laser Doppler measurements of rat gastric mucosal blood flow in a 
gastric chamber after incubation with PBS only over 20 min (control) or PBS solution for  
3 min, followed by 12 mM NaNO2 or NaNO3 solutions for the next 10 min, which were 
replaced by PBS during the last 7 min, as indicated by the horizontal bars. The results are 
expressed as the mean ± S.E.M. of triplicates. 
 
Figure 5. Plasma NOx levels 30, 60, 120 and 180 min after 12 mM oral SNAC administration 
to Swiss mice. The results are expressed as the mean ± S.E.M. (n = 3). * p < 0.05 compared 
to “Before gavage” group, one-way ANOVA with Bonferroni post hoc test. 
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Figure 6. Dose-response of plasma NOx concentration 60 min after 1.2, 12 and 60 mM 
oral SNAC administration. The results are expressed as the mean ± S.E.M. (n = 3). * p < 0.05 
compared to control animals, one-way ANOVA with Bonferroni post hoc test. 
2.4. Discussion 
This is the first study to our knowledge where an ex vivo gastric chamber method was used to 
investigate the effect of luminal SNAC administration on GMBF and where the physiological effects 
of SNAC were correlated with the rates of spontaneous NO release from SNAC solutions. 
Characterization of these rates showed that aqueous SNAC solutions continuously release free NO 
after its formation from NAC S-nitrosation. The initial narrow peaks observed in chemiluminescence 
NO detection (Figure 2) can be assigned to spontaneously released NO by SNAC molecules, which 
accumulates in the solutions prior to analysis. Immediately after solution injection into the NO analyzer 
reaction flask, which is continuously flushed by N2, the accumulated NO is immediately carried to the 
detector, resulting in the observed narrow transient peaks. We confirmed the rapid free NO accumulation 
in SNAC solutions by allowing NO to re-accumulate in the solution after its removal by the instrument’s 
N2 flow, (Figure S3), as interruption of N2 flow after recording the first narrow peak leads to new 
narrow peaks upon N2 flow reestablishment. The plateau signal that follows the initial NO peak reflects 
steady NO production from SNAC during the measurement time period. NO generated in both the 
peak and the plateau comes from the bimolecular reaction of two SNAC molecules to form a 
sulfur-bridged NAC dimer with the concomitant release of two NO molecules according to Scheme 1. 
 
Scheme 1. Spontaneous NO release from SNAC.  
The rate of reaction 1 depends on SNAC concentration, as previously reported [17]. Thus, the rapid 
GMBF increase immediately after luminal SNAC application on the gastric mucosa can be assigned to 
the NO released in reaction 1. Increased GMBF maintenance while the gastric mucosa is incubated 
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with the SNAC solutions is likely due to the approximately constant rate of NO released during the 
plateau phase of SNAC decomposition, as shown in the kinetic curves of Figure 2A,B. NO released in 
scheme 1 is expected to diffuse through the mucous layer of the gastric mucosa, the mucosal capillary 
bed and the muscularis mucosa, reaching the arterial and venous plexuses of the submucosa. Through 
this diffusion process, NO can activate soluble guanylate cyclase (sGC) in the smooth muscle cells 
(SMC) of the mucosal capillary bed and of the arterial and venous plexuses of the submucosa 
microvasculature, including the arterioles and the capillary network, which drains into the venules that 
accompany the arterioles. sGC activation in the microvasculature SMCs elicits a cyclic guanosine 
monophosphate (cGMP)-dependent vasodilatory response, according to the well-known NO-mediated 
vasodilation mechanism [18]. 
The observed GMBF increase can be assigned exclusively to exogenous NO released by SNAC and 
is independent of the endothelium, which is itself a major source of NO and of other vasoactive 
paracrine factors. Although the NO release rate from the 12 mM SNAC solution (14 nmol·mL−1·min−1) 
is 4.7 times higher than from 600 μM SNAC (0.3 nmol·mL−1·min−1), there was no significant difference 
between the maxima GMBF plateaus from these two solutions. These results suggest that the maximum 
subepithelial microcirculation vasodilation was already achieved with 600 μM SNAC. The apparent 
microvasculature tolerance to further increases in blood flow with higher SNAC concentrations is 
likely associated with the maximum mechanically possible SMC relaxation. However, other mechanisms, 
such as the depletion of endogenous species involved in cGMP-dependent NO signaling to vasodilation 
or to metabolic and myogenic mechanisms that operate in the auto-regulatory responses in arteries and 
arterioles to restore blood flow to basal conditions, cannot be ruled out. 
The increased GMBF upon 600 μM SNAC application has great potential to counteract 
NSAID-induced injuries, at least in in the present animal model, considering that a maximum GMBF 
decrease of 25% was observed in indomethacin or diclofenac-treated Sprague Dawley rats [19], while 
in the present study, luminal SNAC application resulted in GMBF increases greater than 250% in the 
same animal model. In contrast, NaNO2 and NaNO3 solutions did not affect GMBF in the conditions 
used in the present study. Although Petersson et al. [20] reported a similar study in which NaNO2 
incubation increased GMBF, the authors used acidic NaNO2 solutions in which NaNO2 is converted to 
nitrous acid (HONO), which undergoes decomposition to release free NO (Scheme 2). 
 
Scheme 2. Nitric oxide release from acid nitrite solution.  
This is also the fate of nitrite coming from the reduction of dietary nitrate, which is known to be 
metabolized in vivo to NO, a pathway involved in the mediation of blood flow regulation [21]. 
Therefore, in the normal situation the administration of nitrite to healthy patients with acidic luminal 
pH, is expected to lead to NO production with consequent GMBF increase. In the ex vivo gastric 
chamber condition of the present study the normal protective effect of the buffered stomach mucous 
layer can be compromised, thus the SNAC, NaNO2 and NaNO3 solutions were buffered at pH 7.4 in 
order to avoid any possible artifact due to gastric acid damage caused by the administration of these 
solutions at the acidic luminal pH 1–2. A special point must be raised for patients receiving proton pump 
2 NO2- + 2 H+              2 HNO2 H2O + NO + NO2
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inhibitor (PPI) co-therapy with NSAIDs. In these cases, the intragastric pH can be higher than 6 [22,23] 
and the administration of nitrite or nitrate to increase GMBF would be ineffective, while SNAC 
administration could enhance the protective action of the PPI therapy. In this respect, the 
characterization of the effects of SNAC, NaNO2 and NaNO3 on the GMBF at pH 7.4 allows proposing 
a potential therapeutic action of SNAC for patients taking PPI. In addition, as nitrate is incapable of 
generating NO in the absence of nitrate reductases, luminal administration of NaNO3 solution at pH 7.4 
was used as a negative control in our study. 
Our chemiluminescence measurements of NO release from 12 mM NaNO2 solution (pH 7.4) 
showed a rate of NO formation of 0.06 nmol·mL−1·min−1, which is fivefold lower than the rate of NO 
released from 600 μM SNAC, and this does not lead to significant blood flow increase as measured by 
Laser Doppler Flowmetry. In the case of 12 mM NaNO3 solution, no equilibrium implying NO production 
can be established in the absence of NO3− to NO2− reducing agents, which in turn, could produce NO 
according to reaction 2. This hypothesis is supported by the absence of vasodilation upon 12 mM 
NaNO3 application (Figure 2D) and the absence of chemiluminescence of NO release. In this case, the 
quantitatively insignificant narrow NO peak (Figure 2D), can be assigned to the presence of trace 
amounts of NaNO2 in the NaNO3 reagent. We also investigated the kinetic behavior of NO release 
from SNAC solutions 600 μM and 12 mM at the pH 1.2 using a simulated gastric fluid (SGF) medium. 
The results obtained are shown in Figure S4 where it can be seen that in the SGF both the NO release 
profile and the rate of NO release from the SNAC solution 600 μM are very similar to those obtained 
at pH 7.4. However, the SNAC solution 12 mM showed a different NO release profile, which led to  
a much higher rate of NO release. The similar behavior of the SNAC 600 μM solution at pH 7.4 and 1.2 
is in accordance with previous studies which showed that GSNO, also a primary S-nitrosothiol, has an 
enhanced stability in highly acidic pH [24]. The higher rate of NO release observed for the SNAC 
solution 12 mM at pH 1.2 may be associated with the catalytic action of trace metal ions present in the 
SGF reagents, and is expected to be more prominent in concentrated S-nitrosothiol solutions, which 
are subjected to autocatalytic effect on their thermal decomposition [17]. For therapeutic purposes, one 
may consider that the less concentrated SNAC solution 600 uM is already capable of promoting the 
maximum GMBF increase, as shown in Figure 4, and that its rate of NO release will not be significantly 
affected by the stomach pH in the range 1.2 to 7.4.  
The profile of plasma NOx levels after SNAC administration shows a significant increase after  
30 min reaching a maximum after 60 min, compared to the basal level. This profile suggests that, 
despite the fast NO release from the SNAC solutions displayed in Figure 2, the increase in plasma 
NOx concentration is governed by the kinetics of NOx absorption in the gastric mucosa, followed by 
the distribution of these species in the systemic circulation. , The decrease of the plasma NOX levels 
after 1 h, reflects the fast diffusion of the primary NO products (NO2− and NO3−) though the stomach 
and intestine and a fast clearance of these anions from the blood. Our results are in accordance with 
those reported by Pannala et al. who found that urinary excretion in humans leads to total nitrate 
clearance in a 24-h period [25]. In addition, the basal NOx levels (approximately 20 μM) are also in 
accordance with previous reports of plasma and urinary NOx levels in animals. For example,  
Fletcher et al. [26] reported plasma NOx levels of approximately 17 μM in naive Lewis rats, compared 
to values up to 56 ± 18 μM under inflammatory conditions after arthritis induction. Amsterdam et al. [27] 
analyzed Wistar rats and rabbits and found basal plasma NOx levels of 34 and 61 μM, respectively. 
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Plasma NOx measurements in diabetic rats also led to values in the same order of magnitude, such as 
those reported by Kino et al. [28] of 20 μM for control Wistar rats and 12 and 14 μM for diabetic 
Wistar rats, a condition of impaired NO production. 
Notably, only oral 12 and 60 mM SNAC administration (corresponding to 70 μmol/kg and  
350 μmol/kg, respectively) led to significant increases in average plasma NOx levels in mice. 
However, luminal 600 μM SNAC administration (a concentration 20 times lower than 12 mM) on rat 
stomachs was sufficient for a marked increase in GMBF. Therefore, the local actions of SNAC, such 
as GMBF increase, do not necessarily imply increases in plasma NOx above basal levels. Similarly, 
other studies have reported therapeutic and protective actions of SNAC using much lower doses and 
concentrations, such as the attenuation of liver fibrosis in cirrhotic rats with 6 μmol/kg/day oral  
SNAC [16], and the reduction of ischemia reperfusion lesions in the steatotic liver [14] and a protection 
of livers during cold storage [29] in rats, both using 0.1 μM SNAC. Therefore, the potential therapeutic 
actions of SNAC may be obtained in an ample concentration range without necessarily impacting the 
homeostatic plasma NOx levels. 
Finally, further studies are necessary to investigate whether SNAC completely decomposes in the 
stomach lumen after administration, and only the free NO diffuses through the gastric mucosa leading 
to GMBF increase with a subsequent plasma NOx increase, or whether intact SNAC also crosses the 
gastrointestinal barrier into the submucosal microcirculation, where it may release NO in situ, also 
leading to GMBF increase. In any case, at a neutral pH, the contribution of exogenous NO2− to free 
NO production is negligible, and both NO2− and NO3− ions likely follow excretion pathways without 
increasing GMBF. These mechanistic possibilities are schematically shown in Figure 7. 
 
Figure 7. Scheme of the major pathways involved in the vasodilation action of SNAC on 
the gastric mucosal blood flow (GMBF) compared to nitrite (NO2−) and nitrate (NO3−) 
anions. Orally or luminally administered SNAC spontaneously releases NO into the 
stomach lumen. Free NO diffuses through the gastric mucosa into the submucosal blood 
vessels, where it increases GMBF. Intact SNAC molecules may also diffuse through the 
gastric mucosa into the submucosal blood vessels, where in situ NO release may lead to 
vasodilation. At neutral pH, NO2− and NO3− anions from oral or luminal sources diffuse to 
the submucosal blood vessels where they contribute to NO-derived NO2− and NO3− levels 
and are excreted without increasing GMBF. The blood vessels of the submucosa are not 
drawn to scale. SNAC, S-nitroso-N-acetylcysteine; NO, nitric oxide. 
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3. Experimental Section  
3.1. SNAC Synthesis  
S-nitroso-N-acetylcysteine (2-acetamido-3-nitrososulfanylpropanoic acid, C5H8N2O4S, MW: 
192.193020 g/mol) was synthesized from equimolar amounts of aqueous NaNO2 and NAC at pH 2, 
which was adjusted with 6 M HCl. The reaction was performed at room temperature with constant 
stirring in an ice bath for 20 min. After the reaction was complete, the acidic solution was neutralized 
to pH 7.0 with NaOH. The final 600 μM and 12 mM SNAC solutions were used immediately. SNAC 
solutions were spectrophotometrically characterized by obtaining their UV-Vis spectra (200–800 nm) 
in the concentration range of 10 to 1000 μM in a quartz cuvette (1 cm optical path) at 25 °C using a 
model 8453 spectrophotometer (Hewlett-Packard, Santa Clara, CA, USA) equipped with a Peltier 
thermostated cell holder (Figure S1). 
3.2. Characterization of NO Release from SNAC, NaNO2 and NaNO3 Solutions 
The spontaneous NO release from 600 μM and 12 mM SNAC solutions in PBS (pH 7.4) was 
characterized by chemiluminescence using a Nitric Oxide Analyzer (NOA 280i, GE Analytical 
Instruments, Boulder, CO, USA) operating at 6.1 psi O2 pressure and 6.5 Torr N2 pressure [30]. A total 
of 5 mL PBS was initially placed in the instrument’s reaction flask and thermostated at 37 °C. After 
baseline stabilization, 600 μM and 12 mM SNAC solutions and 12 mM NaNO2 and NaNO3 solutions 
were analyzed by injecting 100 µL of the individual SNAC, NaNO2 or NaNO3 solutions and by 
monitoring the NO release response over 10 min. The instrument was initially calibrated with standard 
NaNO2 solutions as described previously [31] (Figure S2). Measurements were performed in triplicate 
and are expressed as the mean ± SD. 
3.3. Animal Care  
The present study was performed in accordance with the guidelines of standard humane animal care 
as outlined in the “Guide for the Care and Use of Laboratory Animals”, National Academy Press, 
1996. The Ethical Committee of the University of Campinas approved all animal procedures. The 
study was performed using healthy male Sprague Dawley rats (n = 3) weighing between 250 and 300 g 
and healthy male Swiss mice weighing between 30 and 35 g (n = 4–5). All animals were provided by 
the Multidisciplinary Center for Biological Research in Laboratory Animals of the State University of 
Campinas (CEMIB/Unicamp). All animals were housed in ventilated clean cages (dimensions 30.0 × 
20.0 × 13.0 cm (mice) or 49.0 × 34.0 × 16.0 cm (rats)) in standard housing conditions (12 h light and 
12 h darkness, 25 °C) which were cleaned twice a week. All animals had free access to food and water. 
3.4. Experimental Design  
The effects of local SNAC, NaNO2 and NaNO3 solution administration on GMBF were measured 
using the ex vivo gastric chamber method described by Camara et al. [32]. A pencil probe (type N, 
penetration 1 mm, Transonic Systems, Ithaca, NY, USA) connected to a Laser Doppler Flowmeter 
(BLF 21A, Transonic Systems) was used in all cases. Male Sprague Dawley rats (n = 3), which had 
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been deprived of food but not water for the previous 6 h, were used. The animals were anesthetized 
with halothane and laid supine in a Plexiglas holder heated from an underneath heating pad at 37 °C. 
Their abdomens were opened by midline incision, and the stomach was exposed and carefully opened 
along the greater curvature. The gastric mucosa was exposed, everted onto a 1.5-cm-diameter hole in a 
round Plexiglas plate and pinned along the hole’s perimeter. The pinned gastric mucosal border was 
further clamped with a Plexiglas cylinder, which served as a chamber to apply the solutions to the 
exposed stomach lumen. The gastric mucosa was washed three times with 5 mL PBS (pH 7.4) and 
then incubated in 5 mL PBS (pH 7.4) for three min to record the basal GMBF. The PBS was then 
replaced by fresh PBS (5 mL) in the control animals or by 5 mL aqueous SNAC (600 μM or 12 mM), 
NaNO2 (12 mM) or NaNO3 (12 mM) solution in the treated animals, and the GMBF was monitored for 
10 min. The mucosa was washed again three times with normal PBS, and the SNAC solution was 
replaced by 5 mL PBS (pH 7.4). The GMBF was measured for an additional 7 min. The GMBF values 
were recorded every minute and expressed as perfusion units normalized to control values, which were 
obtained from the PBS bath. Three animals were studied in each group. The animals were killed under 
deep anesthesia by decapitation. 
The time and dose-responses of oral gavage SNAC administration on total plasma NO metabolites 
were assessed by quantifying the sum of NO2− and NO3− levels; the sum was termed NOx. Swiss mice 
were used for gavage experiments instead of Sprague-Dawley rats because they are better suited for 
repeated tail blood collection through tail vein prick with minimal animal restraint and stress, while tail 
blood collection from rats would demand tail tip removal under terminal anesthesia. Swiss male mice 
(n = 4–5) were fasted for 6 h with free access to distilled water and evaluated in gavage experiments. 
To evaluate the time-response of plasma NOx levels, the animals were fasted and gavaged with  
200 μL 12 mM SNAC. Blood samples were collected after 30, 60, 120 and 180 min. To evaluate the 
dose-response of plasma NOx levels, the animals were fasted and gavaged with 200 μL distilled water 
(control group) or 200 μL SNAC solutions at three different concentrations: 1.2, 12 and 60 mM, which 
corresponded to doses of 7, 70 and 350 μmol/kg, respectively. Tail blood was collected after 1 h, at 
which time the maximum NOx level was observed, using a non-surgical microsampling technique. 
Each mouse was removed from the home cage, placed on top of the bench, gently restrained by the 
base of the tail, and the tip of the tail was pricked with a sterile 23–25-gauge needle. The blood sample 
was collected by capillary action using a 10 μL microcapillary tube inserted into a pipette bulb, which 
was placed near the blood sample at the tip of the tail. Blood flow was stopped by applying finger 
pressure to the soft tissue for approximately 20 s before returning the mouse to its home cage. The 
blood samples were dispensed into heparin-coated tubes and centrifuged at 3000 rpm for 30 min at 
room temperature. Plasma NOx levels were measured by chemiluminescence. Briefly, measurements 
were performed by the vanadium chloride method to ensure the complete reduction of NO2− and NO3− 
anions to NO [33]. The vanadium chloride solution (6 mL) was initially placed in the instrument’s 
reaction flask and thermostated at 90 °C. After baseline stabilization, 1 μL of the plasma sample was 
injected, and the NO release signal was monitored. In these measurements, O2 and N2 pressures were 
set at 6.0 psi and 7.0 Torr, respectively. A calibration curve was first obtained from injections (1 µL) 
of five standard NaNO3 solutions in the concentration range of 1 to 1,000 µM. Measurements of each 
sample were performed in triplicate. 
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3.5. Materials 
N-acetylcysteine (NAC), sodium nitrite (NaNO2), sodium nitrate (NaNO3), phosphate buffer saline 
(PBS), vanadium chloride, sodium iodide (KI), glacial acetic acid and hydrochloric acid were 
purchased from Sigma (St. Louis, MO, USA). Deionized water from a Milli-Q purification system was 
used to prepare all solutions. 
3.6. Statistical Analysis 
Results are expressed as mean ± S.E.M. Statistical differences between the groups were analyzed 
using one-way ANOVA followed by Bonferroni post hoc test. A difference with a p < 0.05 was 
considered statistically significant. 
4. Conclusions 
Luminal 600 μM and 12 mM SNAC administration, but not 12 mM NaNO2 or NaNO3 solutions, led 
to a rapid threefold increase in the GMBF of rats, which was maintained throughout the incubation 
with these solutions. This effect correlated to the sixfold higher rate of spontaneous NO release from 
SNAC solutions, compared with equimolar NaNO2 and is in accordance with the absence of NO 
release from the NaNO3 solution. Oral SNAC administration led to a dose-response increase in plasma 
NOx levels compatible with physiological action based on NO release from SNAC. Oral SNAC 
administration may provide a new therapeutic approach for acid-peptic disorder prevention and treatment. 
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